First Tracks Biotherapeutics Inc (TRAX) Stock Statistics & Valuation Metrics

First Tracks Biotherapeutics Inc has a market cap or net worth of $607.83M. The enterprise value is 385.53M.

First Tracks Biotherapeutics Inc has 34,892,380 shares outstanding. The number of shares has decreased by -2.65% in one year.

First Tracks Biotherapeutics Inc’s return on equity (ROE) is -0.58 and return on invested capital (ROIC) is -59.35%.

The current PE Ratio of First Tracks Biotherapeutics Inc is ―. First Tracks Biotherapeutics Inc’s PEG ratio is 0.00.

In the last 12 months, First Tracks Biotherapeutics Inc had revenue of 0.00 and earned -166.09M in profits. Earnings per share was 0.00.

In the last 12 months, operating cash flow was -32.56M and capital expenditures -17.00K, giving a free cash flow of -32.58M billion.

First Tracks Biotherapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―

First Tracks Biotherapeutics Inc upcoming earnings date is May 14, 2026, After Close (Confirmed).

First Tracks Biotherapeutics Inc as a current ratio of 10.20, with Debt / Equity ratio of 0.00%

In the past 12 months, First Tracks Biotherapeutics Inc has paid 0.00 in taxes.

First Tracks Biotherapeutics Inc EV to EBITDA ratio is 1.26, with an EV/FCF ratio of 1.57.

First Tracks Biotherapeutics Inc has $286.45M in cash and marketable securities with $0.00 in debt, giving a net cash position of $286.45M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for First Tracks Biotherapeutics Inc is $37.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy